From: GnRH and LHRgene variants predict adverse outcome in premenopausal breast cancer patients
 | Patients | Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|---|---|
Factor of base model | Number | Percent | HR | 95 percent CI | P value | HR | 95 percent CI | P value |
Age (years) | Â | Â | Â | Â | Â | Â | Â | Â |
   <39 | 54 | 24 | 1.00 |  |  | 1.00 |  |  |
   40–49 | 167 | 60 | 0.72 | 0.50–1.06 |  | 0.66 | 0.44–0.98 |  |
   50–59 | 57 | 21 | 0.42 | 0.23–0.77 | 0.013 | 0.35 | 0.19–0.67 | <0.001 |
Nodal status | Â | Â | Â | Â | Â | Â | Â | Â |
   Negative | 134 | 48 | 1.00 |  |  | 1.00 |  |  |
   Positive | 144 | 52 | 1.90 | 1.34–2.70 | <0.001 | 3.68 | 2.11–6.42 | <0.001 |
Histological grade | Â | Â | Â | Â | Â | Â | Â | Â |
   Poor | 153 | 55 | 1.00 |  |  | 1.00 |  |  |
   Unknown | 59 | 21 | 0.51 | 0.32–0.83 |  | 0.54 | 0.33–0.88 |  |
   Well/moderate | 66 | 24 | 0.55 | 0.36–0.85 | 0.002 | 0.56 | 0.35–0.88 | 0.019 |
Tumor size | Â | Â | Â | Â | Â | Â | Â | Â |
   ≤2 cm | 113 | 41 | 1.00 |  |  | 1.00 |  |  |
   >2 cm | 165 | 59 | 1.77 | 1.23–2.54 | 0.002 | 1.57 | 1.07–2.30 | 0.021 |
Estrogen receptor status | Â | Â | Â | Â | Â | Â | Â | Â |
   Negative | 78 | 28 | 1.00 |  |  | 1.00 |  |  |
   Positive | 200 | 72 | 0.87 | 0.60–1.27 | 0.48 | 1.01 | 0.68–1.49 | 0.96 |
Adjuvant therapy | Â | Â | Â | Â | Â | Â | Â | Â |
   No | 158 | 57 | 1.00 |  |  | 1.00 |  |  |
   Yesa | 120 | 43 | 1.41 | 1.01–1.97 | 0.045 | 0.41 | 0.24–0.70 | 0.001 |
Factors analyzed | Â | Â | Â | Â | Â | Â | Â | Â |
Carriership | Â | Â | Â | Â | Â | Â | Â | Â |
Non-carriersb | Â | Â | 1.00 | Â | Â | 1.00 | Â | Â |
GnRH 16Ser | 121 | 44 | 1.40 | 1.00–1.96 | 0.050 | 1.32 | 0.93–1.88 | 0.12 |
LHR insLQ | 131 | 47 | 1.59 | 1.14–2.23 | 0.007 | 1.64 | 1.16–2.32 | 0.005 |
Combined carriership | Â | Â | Â | Â | Â | Â | Â | Â |
Non-carriers | 87 | 31 | 1.00 | Â | Â | 1.00 | Â | Â |
Only GnRH 16Ser | 60 | 22 | 1.39 | 0.84–2.29 | 0.19 | 1.24 | 0.74–2.08 | 0.42 |
Only LHR insLQ | 70 | 25 | 1.59 | 0.99–2.54 | 0.055 | 1.56 | 0.97–2.51 | 0.067 |
LHR insLQ+GnRH16Ser | 61 | 22 | 2.17 | 1.36–3.48 | 0.001 | 2.14 | 1.32–3.45 | 0.002 |